Amgen/Takeda VEGF Inhibitor Motesanib Faces Setback In NSCLC
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Partners Amgen and Takeda have pinned near-term oncology growth prospects on motesanib, a vascular endothelial growth factor inhibitor for the treatment of non-small cell lung cancer. Now motesanib is facing a setback; Amgen announced Nov. 19 that the Phase III MONET-1 study has been temporarily suspended after a planned safety review showed earlier mortality rates in the treatment group
You may also be interested in...
Cancer Immunotherapy Sees Setback With Failure Of Cell Genesys’ GVAX
Cell Genesys will cut 75 percent of its workforce and explore strategic alternatives after halting development of the prostate cancer vaccine.
Takeda’s Millennium Buy Brings In Potential Cancer Blockbuster Velcade
Takeda made an aggressive move toward its goal of becoming a top three oncology company with the acquisition of Millennium for $8.8 billion
AstraZeneca’s Recentin Will Move Into Phase III For Colorectal Cancer, But Not NSCLC
Firm will study VEGF inhibitor plus chemotherapy versus Genentech’s Avastin in first-line colorectal cancer.